SAFETY AND EFFICACY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, UP TO 24 MONTHS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: INTERIM DATA FROM OPAL BALANCE, AN OPEN-LABEL, LONG-TERM EXTENSION STUDY

被引：5

作者：

Nash, P. ^{[1
]}

Coates, L. C. ^{[2
]}

Kivitz, A. J. ^{[3
]}

Mease, P. J. ^{[4
,5
]}

Gladman, D. D. ^{[6
]}

Covarrubias-Cobos, J. A. ^{[7
]}

Fleishaker, D. ^{[8
]}

Wang, C. ^{[8
]}

Kudlacz, E. ^{[8
]}

Menon, S. ^{[8
]}

Hendrikx, T. ^{[9
]}

Kanik, K. S. ^{[8
]}

机构：

[1] Univ Queensland, Dept Med, Brisbane, Qld, Australia

[2] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England

[3] Altoona Ctr Clin Res, Dept Rheumatol, Duncansville, PA USA

[4] Swedish Med Ctr, Seattle, WA USA

[5] Univ Washington, Seattle, WA 98195 USA

[6] Univ Toronto, Toronto Western Hosp, Dept Med, Toronto, ON, Canada

[7] Unidad Reumatol Las Amer SCP, Merida, Yucatan, Mexico

[8] Pfizer Inc, Groton, CT 06340 USA

[9] Pfizer Inc, Collegeville, PA USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷

关键词：

D O I：

10.1136/annrheumdis-2017-eular.1414

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

FRI0509

引用

页码：682 / 682

页数：1

共 50 条

[21] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Ulcerative Colitis: Open-Label, Long-term Extension Study
Lichtenstein, Gary R.
Loftus, Edward V., Jr.
Bloom, Stuart
Lawendy, Nervin
Friedman, Gary S.
Zhang, Haiying
Wang, Wenjin
Thorpe, Andrew J.
Nduaka, Chudy I.
Su, Chinyu
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S395 - S395
[22] Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study
Hisashi Yamanaka
Yoshiya Tanaka
Tsutomu Takeuchi
Naonobu Sugiyama
Hirotoshi Yuasa
Shigeyuki Toyoizumi
Yosuke Morishima
Tomohiro Hirose
Samuel Zwillich
Arthritis Research & Therapy, 18
[23] Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study
Yamanaka, Hisashi
Tanaka, Yoshiya
Takeuchi, Tsutomu
Sugiyama, Naonobu
Yuasa, Hirotoshi
Toyoizumi, Shigeyuki
Morishima, Yosuke
Hirose, Tomohiro
Zwillich, Samuel
ARTHRITIS RESEARCH & THERAPY, 2016, 18
[24] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Ulcerative Colitis: An Interim Analysis of an Open-Label, Long-Term Extension Study With up to 4.9 Years of Treatment
Lichtenstein, Gary R.
Loftus, Edward V., Jr.
Bloom, Stuart
Lawendy, Nervin
Chan, Gary
Friedman, Gary S.
Zhang, Haiying
Wang, Wenjin
Thorpe, Andrew J.
Nduaka, Chudy I.
Su, Chinyu
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S328 - S328
[25] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Ulcerative Colitis: An Interim Analysis of an Open-Label, Long-Term Extension Study With up to 5.5 Years of Treatment
Lichtenstein, Gary R.
Loftus, Edward V., Jr.
Soonasra, Arif
Lawendy, Nervin
Chan, Gary
Zhang, Haiying
Wang, Wenjin
Thorpe, Andrew J.
Bloom, Stuart
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S413 - S414
[26] Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies
Wollenhaupt, Juergen
Silverfield, Joel
Lee, Eun Bong
Curtis, Jeffrey R.
Wood, Susan P.
Soma, Koshika
Nduaka, Chudy I.
Benda, Birgitta
Gruben, David
Nakamura, Hiroyuki
Komuro, Yoshihiro
Zwillich, Samuel H.
Wang, Lisy
Riese, Richard J.
JOURNAL OF RHEUMATOLOGY, 2014, 41 (05) : 837 - 852
[27] Baricitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: 52 Week Safety and Efficacy in an Open-Label, Long-Term Extension Study
Baker, Milton
Chalabi, Youb
Genovese, Mark
Taylor, Peter
Schlichting, Douglas
Beattie, Scott
Macias, William
Keystone, Edward
JOURNAL OF RHEUMATOLOGY, 2014, 41 (07) : 1505 - 1505
[28] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Clinical and Radiographic Efficacy in Open-Label, Long-Term Extension Studies over 7 Years
Wollenhaupt, Juergen
Silverfield, Joel
Lee, Eun Bong
Terry, Ketti
Kwok, Kenneth
Lazariciu, Irina
Nduaka, Chudy
Connell, Carol A.
DeMasi, Ryan
Wang, Lisy
ARTHRITIS & RHEUMATOLOGY, 2015, 67
[29] Tofacitinib (CP-690,550), An Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Open-Label, Long-Term Extension Studies up to 36 Months.
Wollenhaupt, J.
Silverfield, J. C.
Lee, E. B.
Wood, S.
Soma, K.
Wang, L.
Nakamura, H.
Komuro, Y.
Nduaka, C. I.
Gruben, D.
Zwillich, S. H.
Bradley, J. D.
ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S152 - S153
[30] Long-term Outcomes with Filgotinib, an Oral Selective Janus Kinase 1 Inhibitor: 100-week Data from an Open-label Extension (OLE) Study in Patients with Active Psoriatic Arthritis (PsA)
Coates, Laura
Gladman, Dafna
Van den Bosch, Filip
Helliwell, Philip
Rychlewska-Hanczewska, Anna
Stanislavchuk, Mykola
Gilles, Leen
Gheyle, Lien
Liu, Ke
Trivedi, Mona
Alani, Muhsen
Besuyen, Robin
Mease, Philip
ARTHRITIS & RHEUMATOLOGY, 2020, 72

← 1 2 3 4 5 →